DeepMed Research

RTOG Foundation, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.rtog.org

Clinical Trials

Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Procedure: Surgery
Radiation: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2012-12-20

Last Posted Date: 2025-01-06

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 44

Registration Number: NCT01753414

Locations: 🇨🇳
Shanghai Cancer Center/Fudan University, Shanghai, China
🇨🇳
Chinese Academy of Medical Science, Beijing, China
🇨🇳
Shandong Cancer Hospital, Jinan, Shangdong, China

and more 1 locations

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Phase 3

Active, not recruiting

Conditions: Advanced Adult Primary Liver Cancer
Adult Primary Hepatocellular Carcinoma
Recurrent Adult Primary Liver Cancer

Interventions: Drug: Sorafenib
Radiation: stereotactic body radiation therapy

First Posted Date: 2012-11-21

Last Posted Date: 2025-02-07

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 193

Registration Number: NCT01730937

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States

and more 48 locations

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Phase 2

Completed

Conditions: Adult Glioblastoma
Recurrent Adult Brain Tumor
Adult Giant Cell Glioblastoma
Adult Gliosarcoma

Interventions: Biological: bevacizumab
Radiation: radiation therapy

First Posted Date: 2012-11-21

Last Posted Date: 2022-12-29

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 182

Registration Number: NCT01730950

Locations: 🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸
Bay Area Medical Center, Marinette, Wisconsin, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

and more 28 locations

TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

Phase 2

Completed

Conditions: Non-HPV Locally Advanced Head and Neck Cancer

Interventions: Radiation: IMRT
Drug: Cisplatin
Drug: placebo
Drug: Lapatinib

First Posted Date: 2012-10-22

Last Posted Date: 2023-10-17

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 142

Registration Number: NCT01711658

Locations: 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸
Sutter General Hospital, Sacramento, California, United States
🇨🇦
McGill Cancer Centre at McGill University, Montreal, Quebec, Canada

and more 13 locations

Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer

Phase 3

Completed

Conditions: Perioperative/Postoperative Complications
Gastrointestinal Complications
Cervical Cancer
Endometrial Cancer
Radiation Toxicity
Urinary Tract Toxicity
Urinary Complications

Interventions: Radiation: intensity-modulated radiation therapy
Radiation: Standard radiation therapy

First Posted Date: 2012-08-27

Last Posted Date: 2022-06-15

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 289

Registration Number: NCT01672892

Locations: 🇺🇸
Longmont United Hospital, Longmont, Colorado, United States
🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States

and more 134 locations

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: GnRH agonist
Drug: Anti-androgen
Drug: TAK-700
Radiation: Radiation therapy

First Posted Date: 2012-03-07

Last Posted Date: 2023-04-18

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 239

Registration Number: NCT01546987

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Saint John's Mercy Medical Center, Saint Louis, Missouri, United States

and more 169 locations

Radiation Therapy in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Radiation Toxicity
Sexual Dysfunction
Psychosocial Effects of Cancer and Its Treatment

Interventions: Radiation: 51.6 Gy IMRT
Radiation: 36.25 Gy IMRT

First Posted Date: 2011-09-14

Last Posted Date: 2022-06-09

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 255

Registration Number: NCT01434290

Locations: 🇨🇦
London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
🇺🇸
Emory Crawford Long Hospital, Atlanta, Georgia, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 34 locations

Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery

Completed

Conditions: Adult Diffuse Astrocytoma
Neurotoxicity
Psychosocial Effects of Cancer and Its Treatment
Seizure
Adult Mixed Glioma
Adult Oligodendroglioma
Cognitive/Functional Effects

Interventions: Procedure: cognitive assessment
Procedure: magnetic resonance imaging
Other: laboratory biomarker analysis
Other: questionnaire administration
Procedure: quality-of-life assessment

First Posted Date: 2011-08-16

Last Posted Date: 2015-03-18

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 82

Registration Number: NCT01417507

Locations: 🇺🇸
Waukesha Memorial Hospital, Waukesha, Wisconsin, United States
🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States

and more 38 locations

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Phase 2

Completed

Conditions: Neurotoxicity
Radiation Toxicity
Chemotherapeutic Agent Toxicity
Cognitive/Functional Effects
Lymphoma

Interventions: Biological: Rituximab
Drug: Cytarabine
Drug: Methotrexate
Drug: Procarbazine
Drug: Vincristine
Radiation: low-dose whole-brain radiation therapy

First Posted Date: 2011-07-21

Last Posted Date: 2023-07-20

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 91

Registration Number: NCT01399372

Locations: 🇺🇸
Fresno Cancer Center, Fresno, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 42 locations

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Radiation: radiation therapy
Radiation: Whole-pelvic radiotherapy (WPRT)

First Posted Date: 2011-06-08

Last Posted Date: 2023-08-16

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 2592

Registration Number: NCT01368588

Locations: 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 474 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy